Enoticumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEnoticumab
Drug Alias NameAnti-Delta-Like Ligand 4 monoclonal antibody (Sanofi/Regeneron)Anti-DLL4 monoclonal antibody (Sanofi/Regeneron)SAR-153192REGN-421
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionDelta-like protein 4 inhibitors
TargetsDelta-like protein 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG